The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
Official Title: Randomized Phase II Study of mFOLFOX6 + Bevacizumab or mFOLFOX6 + Cetuximab in Liver Only Metastasis From KRAS Wild Type Colorectal Cancer
Study ID: NCT01836653
Brief Summary: The purpose of this study is to evaluate efficacy and safety of mFOLFOX6+bevacizumab and mFOLFOX6+cetuximab for liver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancer.
Detailed Description: Description: The purpose of this study is to evaluate efficacy and safety of mFOLFOX6+bevacizumab and mFOLFOX6+cetuximab for liver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancer.
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
EPS Corporation, Shinjuku-ku, Tokyo, Japan
Name: Yoshihiko Maehara, MD,PhD,FACS
Affiliation: Graduate School of Medical Science, Kyushu University, Department of Surgery and Science
Role: PRINCIPAL_INVESTIGATOR
Name: Naohiro Tomita, MD, PhD
Affiliation: Hyogo College of Medicine, Department of Surgery
Role: PRINCIPAL_INVESTIGATOR
Name: Ichinosuke Hyodo, MD, PhD
Affiliation: Tsukuba University, Graduate School of Medicine
Role: PRINCIPAL_INVESTIGATOR
Name: Michiaki Unno, MD, PhD
Affiliation: Tohoku University, Division of Gastroenterological Surgery
Role: PRINCIPAL_INVESTIGATOR